AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7733040 — intervention group
Group type: COMPARATOR
Intervention: 2.5 micrograms (100 IU) vitamin D/d
Number of subjects: 247
Study 7733040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 247
Study 1682593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (40 ppm in air)
Number of subjects: 18
Study 1682593 — intervention group
Group type: COMPARATOR
Intervention: Prostacyclin (24 micrograms/h, intravenous infusion)
Number of subjects: 18
Study 6759061 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin (30 to 60 mg daily)
Number of subjects: 86
Study 6759061 — intervention group
Group type: COMPARATOR
Intervention: nortriptyline (75 to 150 mg daily)
Number of subjects: 86
Study 6759061 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 86
Study 6759061 — intervention group
Group type: COMPARATOR
Intervention: nortriptyline
Number of subjects: 86
Study 29847892 — intervention group
Group type: EXPERIMENTAL
Intervention: Irsogladine maleate 2 mg, twice daily (39 patients)
Number of subjects: 100
Study 29847892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (37 patients)
Number of subjects: 100
Study 29149905 — intervention group
Group type: EXPERIMENTAL
Intervention: Kusamala Program (4-day hospital-based intervention)
Number of subjects: 6
Study 29149905 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison arm)
Number of subjects: 6
Study 25772138 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 40156
Study 25772138 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 40156
Study 24228748 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (bilateral needling of acupuncture point ST36 for three days)
Number of subjects: 90
Study 24228748 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 90
Study 21249385 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (Cr) 2 × 5 g/day for 3 weeks
Number of subjects: 16
Study 21249385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 16
Study 19000234 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs with a Jadad score of 3 or greater
Number of subjects: 332
Study 19000234 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially sponsored trials
Number of subjects: 332
Study 19000234 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicentre trials
Number of subjects: 332
Study 19000234 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of reporting of RCTs
Number of subjects: 332
Study 16527244 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllable task-lighting system
Number of subjects: 10
Study 16527244 — intervention group
Group type: COMPARATOR
Intervention: Control group (reference group)
Number of subjects: 10
Study 16527244 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllable task-lighting system with varying dimming speeds
Number of subjects: 10
Study 14739039 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2
Number of subjects: 204
Study 14739039 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 and 100 mg/m2 combined)
Number of subjects: 204
Study 14739039 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (all doses)
Number of subjects: 204
Study 14739039 — intervention group
Group type: COMPARATOR
Intervention: BSC
Number of subjects: 204
Study 11596697 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day regimen (group A): lansoprazole 30 mg p.o. twice daily on day 1, followed by lansoprazole 30 mg p.o. twice daily, amoxicillin 1 g p.o. twice daily, and azithromycin 500 mg p.o. twice daily on days 2 and 3.
Number of subjects: 28
Study 11596697 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-day regimen (group B): lansoprazole 30 mg p.o. twice daily, amoxicillin 1 g p.o. twice daily for two additional days after the three-day regimen.
Number of subjects: 28
Study 11596697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis for group A and group B.
Number of subjects: 28
Study 9723660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 microg once daily
Number of subjects: 105
Study 9723660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 400 microg twice daily
Number of subjects: 105
Study 9723660 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone 7.5 mg once daily
Number of subjects: 105
Study 9723660 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone 15 mg once daily
Number of subjects: 105
Study 9723660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 8045490 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant bolus infusion of Lipiodol containing doxorubicin and mitomycin C
Number of subjects: 50
Study 8045490 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 50
Study 3180298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 2g iv every 12 hours
Number of subjects: 165
Study 3180298 — intervention group
Group type: COMPARATOR
Intervention: Latamoxef 2g iv every 8 hours
Number of subjects: 165
Study 3180298 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin 2g iv every 6 hours
Number of subjects: 165
Study 29882264 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal extreme flexure and hip abduction combined with contralateral side-lying
Number of subjects: 226
Study 29882264 — intervention group
Group type: COMPARATOR
Intervention: Contralateral side-lying alone
Number of subjects: 226
Study 27951511 — intervention group
Group type: EXPERIMENTAL
Intervention: Active prefronto-cerebellar tDCS
Number of subjects: 42
Study 27951511 — intervention group
Group type: COMPARATOR
Intervention: Sham prefronto-cerebellar tDCS
Number of subjects: 42
Study 25709428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia group (received hypoxic air, inspired fraction of oxygen 15%-12%)
Number of subjects: 16
Study 25709428 — intervention group
Group type: COMPARATOR
Intervention: Control group (received normal air, sham hypoxia)
Number of subjects: 16
Study 23467365 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (Ambien), a short‐acting GABAA agonist hypnotic
Number of subjects: 0
Study 23467365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23467365 — intervention group
Group type: COMPARATOR
Intervention: Sodium oxybate (Xyrem)
Number of subjects: 0
Study 23467365 — intervention group
Group type: EXPERIMENTAL
Intervention: Naps with increased spindles
Number of subjects: 0
Study 23467365 — intervention group
Group type: COMPARATOR
Intervention: Control spindles
Number of subjects: 0
Study 20962290 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF α-synuclein oligomers levels in PD patients
Number of subjects: 32
Study 20962290 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF oligomers/total-α-synuclein ratio in PD patients
Number of subjects: 32
Study 18029294 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine GITS
Number of subjects: 7665
Study 18029294 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7665
Study 16075290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes (Quest 1, yield of 0.6 mg) with accurate dose instructions
Number of subjects: 120
Study 16075290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes (Quest 1, yield of 0.6 mg) with no dose instructions
Number of subjects: 120
Study 16075290 — intervention group
Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes (Quest 3, yield of 0.05 mg) with accurate dose instructions
Number of subjects: 120
Study 16075290 — intervention group
Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes (Quest 3, yield of 0.05 mg) with no dose instructions
Number of subjects: 120
Study 12525510 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (3-hour infusion at 175 mg/m2)
Number of subjects: 12
Study 12525510 — intervention group
Group type: COMPARATOR
Intervention: Flat-fixed dose of paclitaxel (300 mg)
Number of subjects: 12
Study 12525510 — intervention group
Group type: EXPERIMENTAL
Intervention: BSA-based dosing
Number of subjects: 12
Study 12525510 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbound and total paclitaxel clearance
Number of subjects: 12
Study 10811496 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (85 mg/m2) and Cisplatin (75 mg/m2) q3w for up to eight cycles
Number of subjects: 48
Study 10811496 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m2)
Number of subjects: 48
Study 10811496 — intervention group
Group type: EXPERIMENTAL
Intervention: TC regimen
Number of subjects: 48
Study 8785111 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment at 50 mJ, 10 pps for 3 minutes
Number of subjects: 11
Study 8785111 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment at 80 mJ, 10 pps for 3 minutes
Number of subjects: 11
Study 8785111 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling
Number of subjects: 11
Study 8785111 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 11
Study 2070108 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units intravenous)
Number of subjects: 11712
Study 2070108 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrinolytic treatment)
Number of subjects: 11712
Study 2070108 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 11712
Study 2070108 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11712
Study 2070108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular events overall
Number of subjects: 11712
Study 2070108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular events
Number of subjects: 11712
Study 7391250 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose alcohol (Incentive Gain)
Number of subjects: 33
Study 7391250 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose alcohol (Incentive Loss)
Number of subjects: 33
Study 7391250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7391250 — intervention group
Group type: COMPARATOR
Intervention: No-dose alcohol
Number of subjects: 33
Study 30846254 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEF score
Number of subjects: 15968
Study 30846254 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEF II score
Number of subjects: 15968
Study 30846254 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalibrated ACEF model
Number of subjects: 15968
Study 26822105 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with 1500 ppm fluoride
Number of subjects: 51
Study 26822105 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste with 0 ppm fluoride
Number of subjects: 51
Study 25465736 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinosad/MO
Number of subjects: 229
Study 25465736 — intervention group
Group type: COMPARATOR
Intervention: CVP (Stronghold)
Number of subjects: 229
Study 25465736 — intervention group
Group type: COMPARATOR
Intervention: CVP (Milbemax)
Number of subjects: 229
Study 23647811 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs infusion
Number of subjects: 20
Study 23647811 — intervention group
Group type: COMPARATOR
Intervention: Control (without n-3 PUFAs)
Number of subjects: 20
Study 23647811 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs infusion and Control
Number of subjects: 20
Study 21354370 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year trastuzumab
Number of subjects: 3398
Study 21354370 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3398
Study 21354370 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective-crossover cohort (non-randomised)
Number of subjects: 3398
Study 19406658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.2 microg/kg/min)
Number of subjects: 42
Study 19406658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (2.0 microg/kg/min)
Number of subjects: 42
Study 19406658 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 42
Study 17680910 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazax (75,000 SQ‐T)
Number of subjects: 60
Study 17680910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14766335 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 11
Study 14766335 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 11
Study 14766335 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 11
Study 14766335 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 to 80 mg/day
Number of subjects: 11
Study 14766335 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 to 40 mg/day
Number of subjects: 11
Study 14766335 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 11
Study 14766335 — intervention group
Group type: COMPARATOR
Intervention: Statins (general)
Number of subjects: 11
Study 11255134 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 19
Study 11255134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Resistance Training and Walking (RT/W)
Number of subjects: 19
Study 11255134 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 19
Study 9531360 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic radiation to the pelvic lymph nodes and prostatic bed (45 Gy in 4.5-5 weeks, plus 65 Gy in 6.5-8 weeks to the prostatic bed)
Number of subjects: 449
Study 9531360 — intervention group
Group type: COMPARATOR
Intervention: Prostatic bed alone (65 Gy in 6.5-8 weeks)
Number of subjects: 449
Study 9531360 — intervention group
Group type: COMPARATOR
Intervention: Staging laparotomy (SL)
Number of subjects: 449
Study 9531360 — intervention group
Group type: COMPARATOR
Intervention: Lymphangiogram (LAG)
Number of subjects: 449
Study 8025759 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-1078 (225 mg)
Number of subjects: 6
Study 8025759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 6
Study 2527051 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (0.34-0.44 mg/kg body weight) + UVB phototherapy (ReUVB)
Number of subjects: 41
Study 2527051 — intervention group
Group type: COMPARATOR
Intervention: UVB phototherapy alone
Number of subjects: 41
Study 2527051 — intervention group
Group type: COMPARATOR
Intervention: Acitretin alone
Number of subjects: 41
Study 2527051 — intervention group
Group type: EXPERIMENTAL
Intervention: ReUVB
Number of subjects: 41
Study 979832 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta9-tetrahydrocannabinol (THC) 10 mg/70 kg
Number of subjects: 12
Study 979832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0-5 g/kg
Number of subjects: 12
Study 979832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of THC and ethanol
Number of subjects: 12
Study 979832 — intervention group
Group type: COMPARATOR
Intervention: Ethanol alone
Number of subjects: 12
Study 31593877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (62 farms)
Number of subjects: 100
Study 31593877 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 farms)
Number of subjects: 100
Study 28222225 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DL-PDT)
Number of subjects: 26
Study 28222225 — intervention group
Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (C-PDT)
Number of subjects: 26
Study 25296725 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2603618 (275 mg i.v. infusion) with desipramine (50 mg oral)
Number of subjects: 30
Study 25296725 — intervention group
Group type: COMPARATOR
Intervention: Desipramine (50 mg oral) alone
Number of subjects: 30
Study 23688282 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy
Number of subjects: 25
Study 23688282 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 25
Study 21693627 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 cm-square with high prediagnostic mammographic density (MD)
Number of subjects: 231
Study 21693627 — intervention group
Group type: COMPARATOR
Intervention: 1 cm-square in the lowest quartile of prediagnostic MD
Number of subjects: 231
Study 21693627 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cm-square grid with high prediagnostic MD
Number of subjects: 231
Study 19194313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir film-coated tablet formulation (LPV/r-fct)
Number of subjects: 70
Study 19194313 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir soft gelatine capsules (LPV/r-sgc)
Number of subjects: 70
Study 17544264 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg
Number of subjects: 19
Study 17544264 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg
Number of subjects: 19
Study 17544264 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 18 microg
Number of subjects: 19
Study 17544264 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 36 microg
Number of subjects: 19
Study 17544264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15386822 — intervention group
Group type: EXPERIMENTAL
Intervention: Oralin spray (100 u)
Number of subjects: 23
Study 15386822 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection (0.1 u/kg)
Number of subjects: 23
Study 11293553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (30 mg/kg/d in 2 divided doses)
Number of subjects: 304
Study 11293553 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (45/6.4 mg/kg/d plus amoxicillin 45 mg/kg/d in 2 divided doses)
Number of subjects: 304
Study 11293553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 304
Study 11293553 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 304
Study 9555662 — intervention group
Group type: COMPARATOR
Intervention: G-699->C polymorphism in the putative promoter region
Number of subjects: 0
Study 9555662 — intervention group
Group type: COMPARATOR
Intervention: A1098->G polymorphism in exon 3
Number of subjects: 0
Study 9555662 — intervention group
Group type: COMPARATOR
Intervention: B2R polymorphism (C181->T)
Number of subjects: 0
Study 8035028 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF), 5 micrograms/kg daily for 10 days
Number of subjects: 24
Study 8035028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2646087 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg twice daily
Number of subjects: 144
Study 2646087 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 144
Study 1106311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation (IPPV)
Number of subjects: 209
Study 1106311 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Positive-Negative Pressure Ventilation (IPNPV)
Number of subjects: 209
Study 1106311 — intervention group
Group type: EXPERIMENTAL
Intervention: IPPV
Number of subjects: 209
Study 1106311 — intervention group
Group type: COMPARATOR
Intervention: IPNPV
Number of subjects: 209
Study 31772347 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS over the premotor cortex
Number of subjects: 0
Study 31772347 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS over the motor hotspot
Number of subjects: 0
Study 30372675 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH treatment
Number of subjects: 0
Study 30372675 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 26239632 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) therapeutic dose (40 mg)
Number of subjects: 56
Study 26239632 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (OM) supratherapeutic dose (160 mg)
Number of subjects: 56
Study 26239632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 26239632 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MOXI; 400 mg)
Number of subjects: 56
Study 24041330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant users (CI)
Number of subjects: 90
Study 24041330 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-simulation condition
Number of subjects: 90
Study 24041330 — intervention group
Group type: COMPARATOR
Intervention: Normal hearing (NH) adults
Number of subjects: 90
Study 24041330 — intervention group
Group type: EXPERIMENTAL
Intervention: Degraded-speech groups (CI users and CI-simulation)
Number of subjects: 90
Study 22291971 — intervention group
Group type: EXPERIMENTAL
Intervention: One-month learning rate
Number of subjects: 0
Study 19827656 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-platelet treatment
Number of subjects: 0
Study 19827656 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous coronary interventions
Number of subjects: 0
Study 19827656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists
Number of subjects: 0
Study 17471136 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin cooling using a cold-air system (SmartCool; Cynosure, Westford, MA)
Number of subjects: 31
Study 17471136 — intervention group
Group type: COMPARATOR
Intervention: Ice cubes
Number of subjects: 31
Study 17471136 — intervention group
Group type: COMPARATOR
Intervention: Cold air blower
Number of subjects: 31
Study 16160603 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid, 10 mg/d for 7 days
Number of subjects: 20
Study 16160603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11872674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol (IV PROP, 80 microg/min)
Number of subjects: 12
Study 11872674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial propranolol (IA PROP, 25 microg/min)
Number of subjects: 12
Study 11872674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phentolamine (IV PHEN, 500 microg/min)
Number of subjects: 12